Maze Therapeutics (NASDAQ:MAZE) CEO Jason Coloma Sells 23,865 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 23,865 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $26.05, for a total value of $621,683.25. Following the completion of the transaction, the chief executive officer owned 319,079 shares of the company’s stock, valued at $8,312,007.95. The trade was a 6.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Price Performance

MAZE stock opened at $26.60 on Thursday. Maze Therapeutics, Inc. has a one year low of $9.83 and a one year high of $53.65. The company’s fifty day moving average price is $25.66 and its 200-day moving average price is $36.14. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The company has a market capitalization of $1.47 billion, a PE ratio of -10.51 and a beta of 2.26.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. On average, equities analysts anticipate that Maze Therapeutics, Inc. will post -2.76 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on MAZE shares. Wedbush boosted their target price on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research report on Monday, March 16th. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Guggenheim lifted their price objective on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Truist Financial lowered their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, April 14th. Finally, JPMorgan Chase & Co. raised their target price on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $66.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP bought a new stake in Maze Therapeutics during the first quarter worth approximately $917,000. Bank of America Corp DE lifted its stake in shares of Maze Therapeutics by 961.3% in the 1st quarter. Bank of America Corp DE now owns 195,084 shares of the company’s stock valued at $5,823,000 after purchasing an additional 176,703 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after purchasing an additional 1,383 shares during the period. Exome Asset Management LLC purchased a new position in shares of Maze Therapeutics in the 1st quarter worth approximately $2,642,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Maze Therapeutics by 111.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 14,570 shares of the company’s stock valued at $435,000 after purchasing an additional 7,673 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.